CRSP CRISPR Therapeutics AG Stock Quote

CRSP [NASD]

Healthcare | Biotechnology | Switzerland

Index	-	P/E	-	EPS (ttm)	-5.62	Insider Own	1.10%	Shs Outstand	75.83M	Perf Week	-1.02%
Market Cap	9.02B	Forward P/E	-	EPS next Y	-6.93	Insider Trans	-28.82%	Shs Float	65.91M	Perf Month	-25.25%
Income	-392.30M	PEG	-	EPS next Q	-1.13	Inst Own	64.30%	Short Float	3.51%	Perf Quarter	-7.81%
Sales	1.10M	P/S	8196.35	EPS this Y	-550.50%	Inst Trans	4.55%	Short Ratio	1.71	Perf Half Y	-26.96%
Book/sh	34.34	P/B	3.52	EPS next Y	-1139.20%	ROA	21.90%	Target Price	163.11	Perf Year	40.13%
Cash/sh	34.76	P/C	3.48	EPS next 5Y	-	ROE	24.10%	52W Range	76.71 - 220.20	Perf YTD	-20.96%
Dividend	-	P/FCF	17.95	EPS past 5Y	-52.50%	ROI	-21.30%	52W High	-45.04%	Beta	2.22
Dividend %	-	Quick Ratio	26.20	Sales past 5Y	23.80%	Gross Margin	-	52W Low	57.76%	ATR	7.10
Employees	410	Current Ratio	26.20	Sales Q/Q	243.30%	Oper. Margin	-	RSI (14)	40.53	Volatility	4.91% 5.20%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	827.70%	Profit Margin	-	Rel Volume	1.05	Prev Close	119.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jul 29 AMC	Payout	0.00%	Avg Volume	1.35M	Price	121.02
Recom	2.10	SMA20	-8.76%	SMA50	-5.62%	SMA200	-8.19%	Volume	1,424,784	Change	1.70%

Jun-14-21

Upgrade

Citigroup

Sell → Neutral

$55 → $132

Apr-21-21

Upgrade

Jefferies

Hold → Buy

$172

Mar-04-21

Initiated

JMP Securities

Mkt Outperform

$160

Dec-10-20

Reiterated

Needham

Buy

$105 → $170

Dec-10-20

Reiterated

Chardan Capital Markets

Buy

$110 → $166

Dec-10-20

Downgrade

Jefferies

Buy → Hold

Dec-07-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$145

Oct-23-20

Initiated

RBC Capital Mkts

Sector Perform

$110

Oct-05-20

Initiated

BofA Securities

Buy

$110

Jul-28-20

Reiterated

Needham

Buy

$84 → $105

Jul-14-20

Initiated

SunTrust

Buy

$140

Jun-15-20

Reiterated

Canaccord Genuity

Buy

$80 → $84

Mar-05-20

Initiated

Stifel

Hold

$52

Feb-03-20

Downgrade

Evercore ISI

Outperform → In-line

$85 → $52

Nov-19-19

Upgrade

William Blair

Mkt Perform → Outperform

Nov-12-19

Upgrade

Oppenheimer

Perform → Outperform

$65

Aug-01-19

Initiated

Jefferies

Buy

$64

Jul-26-19

Initiated

Canaccord Genuity

Buy

$72

Jun-10-19

Initiated

ROTH Capital

Buy

$50

Apr-12-19

Initiated

Evercore ISI

Outperform

Jul-31-21 08:37AM	Better Buy: Vertex vs. CRISPR Motley Fool
Jul-30-21 10:31AM	CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y Zacks
Jul-29-21 06:25PM	CRISPR Therapeutics AG (CRSP) Tops Q2 Earnings and Revenue Estimates Zacks
05:50PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
04:30PM	CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results GlobeNewswire
Jul-24-21 05:33AM	Is CRISPR Therapeutics a Millionaire-Maker Stock? Motley Fool
Jul-23-21 12:33PM	CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards? Zacks
10:20AM	3 Things About CRISPR Therapeutics That Smart Investors Know Motley Fool
Jul-22-21 11:14AM	3 Things About Vertex Pharmaceuticals That Smart Investors Know Motley Fool
Jul-19-21 03:00PM	CRISPR Therapeutics AG (CRSP) to Report Q2 Results: Wall Street Expects Earnings Growth Zacks
Jul-16-21 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know Zacks
11:02AM	Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week Motley Fool
Jul-13-21 10:15AM	Hedge Funds Arent Crazy About CRISPR Therapeutics AG (CRSP) Anymore Insider Monkey
Jul-11-21 07:01AM	Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results Motley Fool
Jul-09-21 04:04PM	A Comprehensive Guide to Genomic ETFs Zacks
Jul-02-21 12:48PM	Here's What Drove Gene Editing Stocks Higher This Week Motley Fool
Jun-30-21 06:42AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals Zacks +7.58%
Jun-29-21 11:20AM	Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data Zacks
09:55AM	3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data Zacks
Jun-28-21 02:36PM	Nasdaq surges to record, FAA stalls Boeing 777X, airline stocks nosedive, AMC & GameStop jump Yahoo Finance Video +6.39%
08:39AM	Gene Editing Data Look Good for Intellia. How It Made History. Barrons.com
03:21AM	We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate Simply Wall St.
Jun-26-21 01:07PM	Gene Editing Data Look Good for Intellia. How It Made History. Barrons.com
Jun-25-21 02:07PM	Crispr Therapeutics Stock Sees Improved Relative Strength Rating Investor's Business Daily
Jun-24-21 11:00AM	Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study Zacks +5.51%
Jun-18-21 05:50PM	CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know Zacks
Jun-16-21 11:25AM	CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases Zacks
Jun-15-21 08:06AM	CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases Benzinga
07:15AM	CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreichs Ataxia GlobeNewswire
06:55AM	Can Vertex Pharmaceuticals Recover From Its Latest Setback? Motley Fool
04:37AM	CRISPR on the Cutting Edge of Gene Editing Technology TipRanks
Jun-14-21 10:50AM	CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data Zacks
08:20AM	CRISPR Therapeutics Is Editing Out Its Correction TheStreet.com
Jun-11-21 04:12PM	Why Crispr's Gene-Editing Jump Wasn't Enough To Help Vertex Stock Investor's Business Daily
10:33AM	Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials Benzinga
03:05AM	Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at European Hematology Association Annual Meeting Business Wire
Jun-08-21 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
Jun-07-21 07:11AM	What's the Best Way to Invest in Genetics Stocks? Motley Fool +5.22%
Jun-06-21 12:16PM	How Much Will the Nkarta Deal Help CRISPR Therapeutics? Motley Fool
Jun-05-21 08:08AM	Is Editas the Best Genetics Stock to Buy? Motley Fool
Jun-04-21 07:21AM	1 Genetics Stock to Put on Your Radar Motley Fool
Jun-02-21 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
May-27-21 11:31AM	CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound? Zacks
May-26-21 06:05AM	4 Unstoppable Healthcare Stocks to Buy on the Dip Motley Fool
May-25-21 04:47PM	10 Best Biotech Stocks to Buy According to Cathie Wood Insider Monkey
08:00AM	CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
May-22-21 09:56AM	10 Best Stocks to Buy in 2021 According to Cathie Wood Insider Monkey
06:25AM	Is Vertex Pharmaceuticals a Buy? Motley Fool
May-12-21 11:00AM	Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress GlobeNewswire
06:14AM	3 Healthcare Stocks That Might Soar if Biden Gets This Part of His Budget Approved Motley Fool
May-11-21 12:12PM	Cathie Woods ARK Wasnt Built for a Flood The Wall Street Journal
06:40AM	Avoid the Dogecoin Crash by Buying These 2 Growth Stocks Instead Motley Fool
May-07-21 11:38AM	Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer Benzinga
06:40AM	With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market Motley Fool
May-06-21 04:01PM	CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer GlobeNewswire -5.32%
May-04-21 06:00AM	This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon Motley Fool -5.76%
May-01-21 06:10AM	Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? Motley Fool
Apr-29-21 10:01PM	Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript Motley Fool
04:17PM	Best Biotech Stocks & ETFs for mRNA, Gene Editing Zacks
08:30AM	CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
03:26AM	Shareholders Are Thrilled That The CRISPR Therapeutics (NASDAQ:CRSP) Share Price Increased 179% Simply Wall St.
Apr-28-21 04:01PM	CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting GlobeNewswire
12:18PM	Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News Zacks
09:56AM	CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y Zacks
Apr-27-21 05:15PM	CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:01PM	CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results GlobeNewswire
01:53PM	Crispr Therapeutics Gets Relative Strength Rating Upgrade Investor's Business Daily
Apr-26-21 02:47PM	Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving Forward Motley Fool +7.25%
08:30AM	Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001 for Transfusion-Dependent Beta Thalassemia GlobeNewswire
Apr-23-21 05:50PM	CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know Zacks
08:09AM	Is a Beat in Store for CRISPR (CRSP) This Earnings Season? Zacks
06:35AM	2 Unstoppable Cathie Wood Stocks That Could Make You Rich Motley Fool
Apr-21-21 02:54PM	Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates Zacks
08:55AM	Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership Zacks
08:10AM	CRISPR Therapeutics Is Upgraded After $900 Million Deal Barrons.com
Apr-20-21 04:29PM	Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics Motley Fool +5.76%
12:31PM	Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for Zacks
10:20AM	Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics Barrons.com
07:15AM	Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia GlobeNewswire
Apr-16-21 03:51PM	CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today InvestorPlace
Apr-10-21 08:31AM	CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function GlobeNewswire
Apr-06-21 02:00PM	Is CRSP Stock A Buy or Sell? Insider Monkey
08:00AM	CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Apr-02-21 08:06AM	Here's the Holy Grail of Gene Editing Motley Fool
Apr-01-21 02:11PM	Crispr Therapeutics Stock Sees Improved Relative Strength Rating Investor's Business Daily
Mar-25-21 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
Mar-23-21 11:00AM	CRISPR Therapeutics Could Suffer Further Steep Losses TheStreet.com
Mar-21-21 06:43AM	2 Cathie Wood Stocks That Are 40% Off Motley Fool
Mar-18-21 06:26PM	Roblox Goes Public, and the Future of CRISPR and Gene Editing Motley Fool -5.74%
11:30AM	CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound? Zacks
Mar-17-21 05:45PM	CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know Zacks
07:03AM	Is CRISPR Therapeutics Stock Poised to Soar Nearly 30%? Motley Fool
Mar-12-21 06:04AM	2 Stocks Cathie Wood Loves That Should Be Bigger Winners Than Tesla Motley Fool
Mar-10-21 05:03PM	CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting GlobeNewswire
11:17AM	Crispr Therapeutics Hits 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
06:30AM	Walter Isaacson, Author of 'The Code Breaker,' On Dr. Jennifer Doudna And CRISPR Gene Editing Motley Fool
Mar-06-21 09:26AM	Cathie Woods Top 10 Stock Picks Insider Monkey
Mar-05-21 05:45PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
07:00AM	Vertex Stock Fell After a Setback on a New Drug. Its an Opportunity for Investors. Barrons.com
Mar-04-21 03:00PM	Is CRISPR Stock Heading to $160 in 2021? Motley Fool

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bolzon Bradley J PhD	Director	Jul 19	Sale	126.43	10,000	1,264,348	148,831	Jul 21 05:21 PM
Novak Rodger	President	Jun 30	Sale	165.00	25,000	4,125,000	573,007	Jul 01 05:43 PM
Bolzon Bradley J PhD	Director	Jun 28	Sale	152.48	10,000	1,524,799	158,831	Jun 30 06:38 PM
Bolzon Bradley J PhD	Director	Jun 28	Sale	152.48	20,375	3,106,783	0	Jun 30 06:38 PM
Novak Rodger	President	Jun 21	Sale	128.62	25,000	3,215,458	623,007	Jun 23 05:54 PM
Kulkarni Samarth	Chief Executive Officer	Jun 15	Option Exercise	12.57	30,000	377,100	217,719	Jun 17 05:44 PM
Kulkarni Samarth	Chief Executive Officer	Jun 15	Sale	126.43	30,000	3,792,804	187,719	Jun 17 05:44 PM
Bolzon Bradley J PhD	Director	Jun 11	Sale	126.61	10,000	1,266,118	20,375	Jun 15 04:41 PM
Bolzon Bradley J PhD	Director	Mar 22	Sale	132.37	30,374	4,020,667	30,375	Mar 24 06:00 PM
Bolzon Bradley J PhD	Director	Feb 19	Sale	149.11	171,003	25,497,840	168,831	Feb 23 04:40 PM
KASINGER JAMES R.	General Counsel and Secretary	Jan 19	Option Exercise	51.49	27,500	1,415,975	49,931	Jan 20 06:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Jan 19	Sale	204.94	27,500	5,635,944	22,431	Jan 20 06:05 PM
Kulkarni Samarth	Chief Executive Officer	Jan 15	Option Exercise	1.81	20,000	36,200	202,989	Jan 20 06:11 PM
Klein Lawrence Otto	CBO & COO	Jan 15	Option Exercise	13.79	25,010	344,776	36,334	Jan 20 06:07 PM
Kulkarni Samarth	Chief Executive Officer	Jan 15	Sale	213.67	20,000	4,273,311	182,989	Jan 20 06:11 PM
Klein Lawrence Otto	CBO & COO	Jan 15	Sale	215.20	25,000	5,379,940	20,000	Jan 20 06:07 PM
Kulkarni Samarth	Chief Executive Officer	Dec 29	Option Exercise	1.81	13,800	24,978	182,989	Dec 30 04:02 PM
Ho Tony W	Executive VP, Head of R&D	Dec 21	Option Exercise	16.90	23,551	398,012	57,515	Dec 22 04:55 PM
Ho Tony W	Executive VP, Head of R&D	Dec 21	Sale	149.23	23,551	3,514,610	33,964	Dec 22 04:55 PM
Bolzon Bradley J PhD	Director	Dec 16	Sale	148.95	7,352	1,095,089	339,834	Dec 18 07:12 PM
Bolzon Bradley J PhD	Director	Dec 16	Sale	148.95	7,648	1,139,177	0	Dec 18 07:12 PM
Kulkarni Samarth	Chief Executive Officer	Dec 10	Option Exercise	1.81	20,000	36,200	189,189	Dec 11 04:05 PM
Kulkarni Samarth	Chief Executive Officer	Dec 10	Sale	142.29	20,000	2,845,782	169,189	Dec 11 04:05 PM
Bolzon Bradley J PhD	Director	Dec 10	Sale	143.35	33,000	4,730,448	314,186	Dec 14 07:11 PM
KASINGER JAMES R.	General Counsel and Secretary	Dec 09	Option Exercise	13.62	22,026	299,994	22,415	Dec 10 04:35 PM
Bolzon Bradley J PhD	Director	Dec 07	Sale	154.53	171,004	26,424,505	347,186	Dec 09 07:54 PM
Novak Rodger	President	Nov 30	Option Exercise	14.21	100,000	1,421,500	698,007	Dec 02 04:26 PM
Novak Rodger	President	Nov 30	Sale	125.00	100,000	12,500,000	648,007	Dec 02 04:26 PM
Novak Rodger	President	Oct 09	Option Exercise	14.43	2,762	39,856	650,769	Oct 13 04:44 PM
Novak Rodger	President	Oct 09	Sale	100.00	2,762	276,200	648,007	Oct 13 04:44 PM
Novak Rodger	President	Oct 08	Option Exercise	14.43	22,238	320,894	670,245	Oct 13 04:44 PM
Novak Rodger	President	Oct 08	Sale	100.00	22,238	2,223,800	648,007	Oct 13 04:44 PM
Bolzon Bradley J PhD	Director	Sep 18	Sale	86.87	3,035	263,636	518,190	Sep 22 08:10 PM
Bolzon Bradley J PhD	Director	Sep 16	Sale	86.98	8,965	779,777	521,225	Sep 18 04:30 PM
Bolzon Bradley J PhD	Director	Sep 14	Sale	84.89	1,155	98,045	530,190	Sep 16 08:00 PM
Bolzon Bradley J PhD	Director	Sep 10	Sale	85.36	22,845	1,949,996	531,345	Sep 11 09:49 PM
Novak Rodger	President	Sep 01	Option Exercise	14.36	25,000	359,059	673,007	Sep 03 04:44 PM
Bolzon Bradley J PhD	Director	Sep 01	Option Exercise	25.23	60,000	1,513,950	60,000	Sep 03 09:21 PM
TOMSICEK MICHAEL JOHN	Chief Financial Officer	Sep 01	Option Exercise	17.75	12,000	213,000	12,410	Sep 03 04:46 PM
Novak Rodger	President	Sep 01	Sale	92.62	25,000	2,315,578	648,007	Sep 03 04:44 PM
Bolzon Bradley J PhD	Director	Sep 01	Sale	92.51	60,000	5,550,644	0	Sep 03 09:21 PM
TOMSICEK MICHAEL JOHN	Chief Financial Officer	Sep 01	Sale	92.26	12,000	1,107,068	410	Sep 03 04:46 PM
Novak Rodger	President	Aug 19	Option Exercise	14.00	25,000	350,000	673,007	Aug 21 04:11 PM
Novak Rodger	President	Aug 19	Sale	100.00	25,000	2,500,000	648,007	Aug 21 04:11 PM
TOMSICEK MICHAEL JOHN	Chief Financial Officer	Aug 03	Option Exercise	17.75	12,000	213,000	12,410	Aug 05 04:20 PM
TOMSICEK MICHAEL JOHN	Chief Financial Officer	Aug 03	Sale	86.74	12,000	1,040,919	410	Aug 05 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience